Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

COPD-asthma-devices-market2025 PORTLAND, DE, UNITED STATES, January 29, 2025 /EINPresswire / -- Day-to-day exposure to environmental pollutio ...

Chronic pain is a common complaint among those with COPD. Columnist Caroline Gainer shares the pain relief strategies that ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

A recent trial showed that nicotinamide riboside supplementation might reduce airway inflammation in patients with COPD who ...

In today’s fast-paced world, respiratory issues have become increasingly common, affecting individuals of all ages. Whether it’s due to environmental pollutants, allergens, or chronic conditions like ...

We've all felt winded when taking the stairs or dealt with a cough from time to time. But if these issues linger, they could ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex ...

“Patients with mild-to-moderate COPD who have low exercise tolerance are likely to experience poor respiratory health outcomes,” the investigators concluded. “Exercise tolerance may be considered one ...

Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Centre, a national research platform led by Nanyang Technological University, Singapore’s (NTU Singapore) Lee Kong Chian School of Medicine (LKCMedicine), will lead a multi-institutional research ...